Skip to main content

Table 5 Univariate and multivariate Cox regression analysis of recurrence-free survival

From: Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors

Characteristics Univariate analysis SHMT2 ASCT2
   Multivariate analysis Multivariate analysis
  P value Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Protein expression high vs. low   1.54 (1.16–2.04) 0.003 1.31 (1.01–1.71) 0.042
Age at surgery (years) <0.001 1.04 (1.02–-1.07) <0.001 1.04 (1.02–1.06) <0.001
Tumor size <0.001 Not included   Not included  
 <2 cm      
  ≥ 2–5 cm     
 >5 cm     
Histology 0.11 Not included   Not included  
 Ductal vs. non-ductal      
T stage <0.001     
 T1 vs. ≥T2   1.77 (1.15–2.74) 0.01 1.80 (1.16–2.80) 0.009
Grade <0.001     
 I   Reference   Reference  
 II   1.79 (0.65–4.98) 0.262 1.85 (0.66–5.14) 0.24
 III   2.18 (0.75–6.35) 0.154 2.64 (0.92–7.59) 0.072
Nodal status <0.001     
 N0 vs. ≥N1   1.62 (1.10–2.40) 0.015 1.59 (1.07–2.35) 0.021
Menopausal status 0.01     
 Pre/peri vs. postmenopausal   0.65 (0.31–1.38) 0.263 0.73 (0.35–1.54) 0.41
Receptor status
 ER- vs. ER+ <0.001 Not included   Not included  
 PgR- vs. PgR+ <0.001 Not included   Not included
 HER2- vs. HER2+ 0.489 Not included   Not included
 HR- vs. HR+ <0.001 0.79 (0.49–1.27) 0.334 0.69 (0.43–1.10) 0.115
Receptor-defined subtypes <0.001 Not included   Not included  
 Luminal A-like      
 Luminal B-like (HER2 positive)     
 Luminal B-like (HER2 negative)     
 HER2 positive (non-luminal-like)     
 TNBC     
  1. SHMT2 serine hydroxymethyltransferase 2, ASCT2 ASC amino-acid transporter 2, CI confidence interval, Pre-peri premenopausal/perimenopausal, ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor 2, TNBC triple negative breast cancer
  2. A p value <0.05 was considered statistically significant